Sinusitis News and Research

Latest Sinusitis News and Research

Conservative therapies recommended over routine use of OTC cough/cold products in children

Despite their widespread use by parents and caregivers, over-the-counter cold and cough medicines have carried a warning by the FDA since 2008, and still have the potential to cause serious adverse events in infants and children. Conservative therapies, including nasal suctioning, humidification, and nasal saline, should be recommended over routine use of OTC cough/cold products in infants and children, according to a new commentary published in the May 2010 issue of Otolaryngology - Head and Neck Surgery.

3 May 2010

ViroPharma initiates multi-dose Phase 2 study of Cinryze in patients with HAE

ViroPharma Incorporated today announced that it has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous versus intravenous administration of Cinryze (C1 esterase inhibitor [human)] in 24 adolescents and adult subjects with hereditary angioedema.

27 Apr 2010

BUSM professor receives Individual Biomedical Research Award

Richard Goldstein, PhD, a professor of pediatrics, division of pediatric infectious diseases, at Boston University School of Medicine, has been awarded an Individual Biomedical Research Award by The Hartwell Foundation and will receive $300,000 over three years as a Hartwell Investigator for his project titled, "A Vaccine Against Streptococcus Pneumoniae Based on Bacterial Surface Proteins Phylogenically Certified as Highly Conserved."

23 Apr 2010

Medtronic named 2010 MDEA winner for excellence in medical device design

Medtronic announced today that the company was named a 2010 Medical Device Excellence Award winner for excellence in medical device design for its Hydrodebrider System, manufactured by the company's Ear Nose and Throat business unit.

9 Apr 2010

Adolescent inhalant misuse can lead to deadly consequences

Approximately 143,000 young people aged 12 to 17 used inhalants in the past year while dealing with a condition like pneumonia, bronchitis, asthma, or sinusitis, according to a new study sponsored by the Substance Abuse and Mental Health Services Administration (SAMHSA). The study determined that the rate of use was 4.4 percent among adolescents who had at least one of the aforementioned respiratory conditions, similar to the rate among adolescents overall (4.1 percent).

8 Apr 2010

Encouraging results from OptiNose's sumatriptan Phase II study for migraine

OptiNose, a leader in nasal drug delivery systems, is pleased to announce the publication in Cephalalgia of results from its Phase II clinical study investigating the efficacy and tolerability of its novel, intranasal drug/device product for the treatment of migraine.

8 Apr 2010

ViroPharma initiates Phase 2 clinical study to evaluate Cinryze

ViroPharma Incorporated today announced that it has initiated an open-label, single-dose Phase 2 study to evaluate doses of Cinryze™ (C1 esterase inhibitor [human)] for treatment of acute angioedema attacks in children less than 12 years of age with hereditary angioedema.

31 Mar 2010

EMA accepts MAA filing of ViroPharma's Cinryze for HAE

ViroPharma Incorporated today announced that the European Medicines Agency (EMA) has accepted the filing of its Marketing Authorization Application for Cinryze for acute treatment and prophylaxis against hereditary angioedema, which was submitted through the centralized procedure in March 2010. ViroPharma is seeking European approval for both prevention and treatment of acute attacks of hereditary angioedema.

25 Mar 2010

China Sky One Medical prepares for commercial launch 13 new SFDA approved products

China Sky One Medical, Inc., a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China, today announced the pending commercial launch of 13 new SFDA approved products over the next few quarters.

22 Mar 2010

ViroPharma to present Cinryze data at Southern European Allergy Society congress

ViroPharma Incorporated today announced the presentation of two abstracts relating to Cinryze™ (C1 esterase inhibitor [human]) therapy at the First International Congress of the Southern European Allergy Society in Florence, Italy.

19 Mar 2010

ViroPharma launches 'Ryze Above' for patients with HAE enrolled in CINRYZESolutions support program

ViroPharma Incorporated today announced the launch of 'Ryze Above' (www.ryzeabove.com), an exclusive patient resources program within the company's patient support program, CINRYZESolutions®. The Ryze Above program was created for HAE patients prescribed Cinryze, the first and only drug specifically approved to help prevent swelling and/or painful attacks in teenagers and adults with HAE.

19 Mar 2010

Post-marketing safety studies for LABAs: AstraZeneca confident of SYMBICORT in treatment of asthma

On March 10-11, 2010, the Joint Advisory Committees of the U.S. Food and Drug Administration (FDA) -- including the Pulmonary-Allergy Drugs and the Drug Safety and Risk Management Advisory Committees -- discussed the design of post-marketing safety studies for long-acting beta-agonist (LABA)-containing products in the U.S., including SYMBICORT® (budesonide/formoterol fumarate dihydrate).

12 Mar 2010

Merck’s MF/F Phase III study data presented at AAAAI annual meeting

Data from two Phase III studies of Merck’s investigational fixed-dose combinations of mometasone furoate and formoterol fumarate (MF/F) were presented by researchers today in two poster presentations at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting.

3 Mar 2010

Balloon Sinuplasty minimally invasive surgery safe for treating chronic sinusitis in children

A recently published study in the American Journal of Rhinology and Allergy demonstrates Balloon Sinuplasty™ technology to be safe when used by physicians in pediatric patients. Known as the INTACT study, this is a prospective, non-randomized, multicenter study and was sponsored by Acclarent, Inc.

2 Mar 2010

FDA's warning over LABA medications for asthma: AANMA offers guidance

Today Allergy & Asthma Network Mothers of Asthmatics (AANMA) offered guidance to help patients understand recent Food and Drug Administration (FDA) warnings about Advair ® (fluticasone and salmeterol), Foradil ® (formoterol), Severent ® (salmeterol) and Symbicort ® (budesonide and formoterol), daily inhaled medications containing a long-acting beta agonist (LABA, a 12-hour bronchodilator).

24 Feb 2010

EndoSheath Systems advantageous over germicidal immersion in preventing flexible ENT scope contamination

Results of a clinical study presented Thursday, Feb. 4 at the annual Triological Society meetings in Orlando, Fla., suggest a sterile barrier sheath system has distinct advantages over germicidal immersion processes used to prevent contamination of fiberoptic nasopharyngolaryngoscopes (flexible ENT scopes). Flexible ENT scopes are used by otolaryngologists to examine the nose and throat area for various disorders such as dysphagia, reflux disease, snoring, and chronic sinusitis.

6 Feb 2010

Romark Laboratories commences enrollment in Alinia clinical trial for acute uncomplicated influenza

Romark Laboratories announced that it has initiated enrollment of patients in a clinical trial of Alinia® (nitazoxanide) for treating acute uncomplicated influenza including illness caused by the currently circulating H1N1 strain.

1 Feb 2010

Study shows benefits of endoscopic sinus surgery for patients with chronic sinusitis

Adults with chronic rhinosinusitis -a debilitating inflammation of the nasal passages that lasts for months and keeps coming back - report significantly improved quality of life following minimally invasive endoscopic sinus surgery, according to a new study led by Oregon Health & Science University (OHSU).

28 Jan 2010

ViroPharma signs agreement with Sanquin Blood Supply Foundation to develop and commercialize Cinryze

ViroPharma Incorporated today announced that it has signed an agreement with Sanquin Blood Supply Foundation for rights to develop, file regulatory dossiers, and commercialize Cinryze(TM) (C1 esterase inhibitor [human]) for hereditary angioedema (HAE) as well as for potential new indications in certain European and rest of world (ROW) territories.

12 Jan 2010

Sinexus renamed as Intersect ENT; begins clinical study on new bioabsorbable stent

Sinexus has changed its name to Intersect ENT. Intersect's initial focus is a bioabsorbable drug eluting stent to treat patients with chronic sinusitis, a debilitating condition that affects 37 million people each year and is more prevalent than heart disease or asthma.

8 Jan 2010

Sinusitis News and Research

Latest Sinusitis News and Research

Conservative therapies recommended over routine use of OTC cough/cold products in children

ViroPharma initiates multi-dose Phase 2 study of Cinryze in patients with HAE

BUSM professor receives Individual Biomedical Research Award

Medtronic named 2010 MDEA winner for excellence in medical device design

Adolescent inhalant misuse can lead to deadly consequences

Encouraging results from OptiNose's sumatriptan Phase II study for migraine

ViroPharma initiates Phase 2 clinical study to evaluate Cinryze

EMA accepts MAA filing of ViroPharma's Cinryze for HAE

China Sky One Medical prepares for commercial launch 13 new SFDA approved products

ViroPharma to present Cinryze data at Southern European Allergy Society congress

ViroPharma launches 'Ryze Above' for patients with HAE enrolled in CINRYZESolutions support program

Post-marketing safety studies for LABAs: AstraZeneca confident of SYMBICORT in treatment of asthma

Merck’s MF/F Phase III study data presented at AAAAI annual meeting

Balloon Sinuplasty minimally invasive surgery safe for treating chronic sinusitis in children

FDA's warning over LABA medications for asthma: AANMA offers guidance

EndoSheath Systems advantageous over germicidal immersion in preventing flexible ENT scope contamination

Romark Laboratories commences enrollment in Alinia clinical trial for acute uncomplicated influenza

Study shows benefits of endoscopic sinus surgery for patients with chronic sinusitis

ViroPharma signs agreement with Sanquin Blood Supply Foundation to develop and commercialize Cinryze

Sinexus renamed as Intersect ENT; begins clinical study on new bioabsorbable stent

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Sinusitis News and Research

Latest Sinusitis News and Research

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Newsletters you may be interested in